Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis

BACKGROUND & OBJECTIVES: FOLFIRINOX and gemcitabine plus nab-paclitaxel (GN) are the most commonly used regimens in advanced pancreatic ductal adenocarcinomas (PDACs). As there is limited data on comparison of these two regimens, the present study was aimed to compare survivals and tolerance for...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramaswamy, Anant, Shah, Darshit, Bhargava, Prabhat, Srinivas, Sujay, Kannan, Sadhana, Shah, Minit, Suman, Mannavi, Das, Shasanka, Trikha, Mehak, Ostwal, Vikas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Practice: Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284354/
https://www.ncbi.nlm.nih.gov/pubmed/37040228
http://dx.doi.org/10.4103/ijmr.ijmr_980_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284354/
https://www.ncbi.nlm.nih.gov/pubmed/37040228
http://dx.doi.org/10.4103/ijmr.ijmr_980_21

Ejemplares similares